咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Feasibility Study for Biweekly... 收藏

Feasibility Study for Biweekly Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer Patients in a Japanese Population

Feasibility Study for Biweekly Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer Patients in a Japanese Population

作     者:Shuichi Tsukamoto Koji Yamazaki Ryo Mori Masakazu Katsura Hidenori Kouso Daigo Kawano Chie Ushijima Sadanori Takeo 

作者机构:Division of General Thoracic Surgery Respiratory Center and Clinical Research Institute National Hospital Organization Kyushu Medical Center Fukuoka City Japan 

出 版 物:《Advances in Lung Cancer》 (肺癌(英文))

年 卷 期:2014年第3卷第1期

页      面:1-9页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:NSCLC Adjuvant Chemotherapy Cisplatin and Vinorelbine Biweekly 

摘      要:Purpose: To evaluate the feasibility of biweekly administration of cisplatin and vinorelbine as adjuvant chemotherapy for patients with completely resected non-small cell lung cancer (NSCLC). Patients and Methods: This was a single-arm, single-institutional study. Patients with completely resected NSCLC (p-Stage IB-IIIA) with no previous chemotherapy or radiotherapy were eligible. Simon’s optimal two-stage design was applied. Both cisplatin (50 mg/m2) and vinorelbine (25 mg/m2) were given on days 1 and 15, every 28 days. The primary endpoint of this study was the feasibility of this combination in the four cycles of treatment. Results: Twenty patients (19 lobectomies and 1 pneumonectomy) were enrolled in this study. 10 (50%) of patients had grade 3/4 neutropenia, and 3 (15%) had grade 3/4 anemia. Severe non-hematologic toxicities were uncommon in this series. No treatment-related death was encountered. 18 (90%) patients completed the planned 4 cycles of chemotherapy. The median intensity was 24.3 (range 18.1 to 25) mg/m2/week with an average of 23.6 (21 - 25) mg/m2/week cisplatin and 12.5 (range 10 to 12.5) mg/m2/week with an average of 12.3 (10 - 12.5) mg/m2/week vinorelbine. The median relative dose intensity of cisplatin was 97.5% (range 72.5% to 100%) with an average of 94.6% (72.5% - 100%) and that of vinorelbine was 100% (range 80% to 100%) with an average of 97.8% (80% - 100%). Conclusion: This regimen is feasible in the treatment of patients with completely resected NSCLC. A phase III trial is warranted to assess the efficacy of this regimen at promoting survival and preventing recurrence.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分